Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AA54
|
| gptkbp:blackBoxWarning |
serious infections caused by encapsulated bacteria
|
| gptkbp:brand |
gptkb:Aspaveli
|
| gptkbp:developer |
gptkb:Apellis_Pharmaceuticals
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:pegcetacoplan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Empaveli
|
| gptkbp:indication |
treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
complement C3 inhibitor
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
diarrhea
abdominal pain fatigue injection site reaction infections |
| gptkbp:usedFor |
gptkb:paroxysmal_nocturnal_hemoglobinuria
|
| gptkbp:bfsParent |
gptkb:Apellis_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|